Rockefeller Capital Management
DNA icon

Rockefeller Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Rockefeller Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.1K Buy
8,337
+425
+5% +$3.54K ﹤0.01% 3264
2025
Q4 		$65.7K Sell
7,912
-3,135
-28% -$33.8K ﹤0.01% 2942
2025
Q3 		$161K Buy
+11,047
New +$132K ﹤0.01% 2338
2024
Q2 		– Sell
-13,754
Closed -$638K – 1651
2024
Q1 		$638K Buy
13,754
+1,902
+16% +$98.5K ﹤0.01% 1395
2023
Q4 		$801K Buy
11,852
+337
+3% +$20.6K ﹤0.01% 1221
2023
Q3 		$834K Buy
11,515
+1,578
+16% +$126K ﹤0.01% 1147
2023
Q2 		$739K Sell
9,937
-2,430
-20% -$144K ﹤0.01% 1195
2023
Q1 		$657K Buy
12,367
+8
+0.1% +$507 ﹤0.01% 1231
2022
Q4 		$834K Sell
12,359
-2,403
-16% -$221K ﹤0.01% 1080
2022
Q3 		$1.84M Sell
14,762
-462
-3% -$55.1K 0.01% 782
2022
Q2 		$1.45M Buy
15,224
+1,341
+10% +$164K 0.01% 872
2022
Q1 		$2.24M Buy
13,883
+3,869
+39% +$753K 0.01% 766
2021
Q4 		$3.33M Buy
10,014
+3,392
+51% +$1.61M 0.02% 664
2021
Q3 		$3.07M Buy
+6,622
New +$3.22M 0.02% 624

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's DNA Position: Q1 2026 in Review

Rockefeller Capital Management increased its Ginkgo Bioworks (DNA) stake by 5.4% in Q1 2026, buying an estimated $3.54K and bringing the position to 8,337 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3264.

Rockefeller Capital Management first reported a position in DNA in Q3 2021 and has held it in 14 quarters since. The position peaked at $3.33M in Q4 2021. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Rockefeller Capital Management held 8,337 shares of Ginkgo Bioworks worth $51.1K as of Q1 2026.
  • Rockefeller Capital Management bought 425 Ginkgo Bioworks shares in Q1 2026, an estimated $3.54K.
  • Ginkgo Bioworks made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3264 holding.
  • Rockefeller Capital Management first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 14 quarters since.
  • Rockefeller Capital Management's Ginkgo Bioworks position peaked at $3.33M in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.